Abstract

The human gut microbiome, the trillions of microorganisms residing in the gastrointestinal
tract, has emerged as a powerful, non invasive biomarker of population health and individual
disease risk. This comprehensive review synthesizes evidence from 150 studies (2010- 2025)
examining the gut microbiome's potential as a predictive, diagnostic, and prognostic
biomarker across major disease categories. We analyze the taxonomic and functional
signatures associated with cardiometabolic disease (obesity, type 2 diabetes, cardiovascular
disease), inflammatory bowel disease, colorectal cancer, liver disease, neuropsychiatric
conditions (depression, anxiety, autism, Parkinson's disease), and immune mediated disorders. Evidence demonstrates that specific microbial compositions (dysbiosis) and functional
pathways (e.g., short chain fatty acid production, bile acid metabolism, trimethylamine N
oxide synthesis) correlate with disease presence, severity, and progression. Microbiome based
risk scores outperform traditional risk factors for some conditions. The gut microbiome
integrates dietary, environmental, lifestyle, and genetic exposures, offering a holistic snapshot
of physiological state. Challenges include high inter individual variability, lack of causal
inference, and methodological standardization. We recommend large scale population cohorts
with longitudinal sampling, machine learning integration, causal validation using animal
models and human intervention studies, and development of clinical microbiome diagnostics. The gut microbiome is not yet ready for routine clinical use but is the most promising novel
biomarker class in a generation.